Interaction between cisplatin and gemcitabine in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Seminars in Oncology

• Publication date

  1995-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 7481849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin

  2004cited by this paper
• Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

  1994cited by this paper
• Gemcitabine: current status of phase I and II trials.

  1994cited by this paper
• Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.

  1994cited by this paper
• The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

  1993cited by this paper
• 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.

  1993cited by this paper
• Transformation of mouse fibroblasts with the oncogenes H‐ras or trk is associated with pronounced changes in drug sensitivity and metabolism

  1993cited by this paper
• Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

  1993cited by this paper
• Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.

  1991cited by this paper
• Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

  1991cited by this paper
• Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.

  1991cited by this paper
• Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing.

  1991cited by this paper
• Formation of interaction products of carboplatin with DNA in vitro and in cancer patients.

  1991cited by this paper
• Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.

  1991cited by this paper
• Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.

  1990cited by this paper
• Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

  1990cited by this paper
• Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.

  1990cited by this paper
• Stereoselective, strong inhibition of ribonucleotide reductase from E. coli by cisplatin.

  1989cited by this paper
• Combination Chemotherapy with Cytosine Arabinoside (Ara‐C) and cis‐Diamminedichloroplatinum (CDDP) for Squamous Cancers of the Upper Aerodigestive Tract

  1989cited by this paper
• 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.

  1989cited by this paper
• In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II).

  1988cited by this paper
• Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid.

  1988cited by this paper
• Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

  1988cited by this paper
• Interactions of cis-diamminedichloroplatinum(II) with 1-beta-D-arabinofuranosylcytosine in LoVo colon carcinoma cells.

  1987cited by this paper
• Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

  1987cited by this paper
• Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.

  1986cited by this paper
• Effects of cis-diamminedichloroplatinum on DNA incorporation and cytotoxicity of 1-beta-D-arabinofuranosylcytosine.

  1986cited by this paper
• Enhanced therapeutic effect of cis-diamminedichloroplatinum(II) against nude mouse grown human pancreatic adenocarcinoma when combined with 1-beta-D-arabinofuranosylcytosine and caffeine.

  1985cited by this paper
• Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine.

  1981cited by this paper
• Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation.

  1981cited by this paper
• Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.

  1977cited by this paper
• Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II).

  1976cited by this paper

• Significance of mouse xenograft tumor model using patient-derived cancer organoids for clinical drug development

  2025cites this paper
• Nucleo(s)tide metabolism as basis for drug development; the Anne Simmonds award lecture

  2024cites this paper
• Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279

  2024cites this paper
• Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer

  2023cites this paper
• Chemosensitivity of three patient-derived primary cultures of canine pericardial mesothelioma by single-agent and combination treatment

  2023cites this paper
• Cisplatin for cancer therapy and overcoming chemoresistance

  2022cites this paper
• Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma

  2022cites this paper
• Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy

  2021cites this paper
• Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis

  2021cites this paper
• Investigation of nucleic acid damage induced by a novel ruthenium anti-cancer drug using multiple analytical techniques: Sequence specificity and damage kinetics.

  2021cites this paper
• Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer

  2021cites this paper
• Incidence of Acute Kidney Injury among Adult Cancer Patients Receiving Nephrotoxic Chemotherapy at King Abdulaziz University Hospital

  2020cites this paper
• A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes

  2020cites this paper
• Interactions of Cisplatin and Daunorubicin at the Chromatin Level

  2020cites this paper
• Cytolytic Epstein-Barr Virus Reactivation Therapy for EBV-Associated Gastric Carcinoma

  2020cites this paper
• Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• CMAR_A_215585 8277..8284

  2019cites this paper
• Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines

  2019cites this paper
• Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China

  2019cites this paper
• High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing.

  2019cites this paper
• Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth

  2018cites this paper
• Gemcitabine and Carboplatin in Inoperable, Loco-Regionally Advanced and Metastatic Gallbladder Cancer- A Study from Northern Indian Cancer Institute

  2017cites this paper
• Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

  2017cites this paper
• A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice

  2017cites this paper
• Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer

  2016cites this paper
• Biweekly dose‐dense gemcitabine–oxaliplatin and dexamethasone for relapsed/refractory aggressive non‐Hodgkin lymphoma: A multicenter, single‐arm, phase II trial

  2016cites this paper
• Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.

  2016cites this paper
• Improving platinum-based treatments for advanced non-small cell lung cancer

  2016cites this paper
• Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer.

  2016cites this paper
• Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis

  2016cites this paper
• Synthetic lethality in lung cancer and translation to clinical therapies

  2016cites this paper
• Gemcitabine and cisplatin in inoperable, loco-regionally advanced and metastatic gallbladder cancer: A study from Northern India cancer institute

  2016cites this paper
• Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer

  2015cites this paper
• Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.

  2015cites this paper
• Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer.

  2015cites this paper
• Neoadjuvant Chemotherapy A New Therapeutic Challenge in Treatment of Ovarian Cancer- A Review

  2015cites this paper
• Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies

  2015cites this paper
• Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer

  2014cites this paper
• The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients

  2014cites this paper
• GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma

  2014cites this paper
• Gemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment

  2014cites this paper
• Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer

  2013cites this paper
• Determination of the activity of bnips derivative compounds incorporated into liposomes against pancreatic tumor cells

  2013cites this paper
• Platinum-Based Chemotherapy : A Three-Dimensional ( 3-D ) , Polyacrylamide Gel-Based DNA Microarray Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with

  2013cites this paper
• Phase II Trial of Combination Chemotherapy with Gemcitabine, 5-Fluorouracil and Cisplatin for Advanced Cancers of the Bile Duct, Gallbladder, and Ampulla of Vater

  2013cites this paper
• [Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer].

  2013cites this paper
• Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma

  2013cites this paper
• Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.

  2013cites this paper
• Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.

  2013cites this paper
• A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.

  2013cites this paper
• treatment of pulmonary metastases Combination chemotherapy with gemcitabine with isolated lung perfusion for the

  2013cites this paper
• Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with Platinum-Based Chemotherapy: A Three-Dimensional (3-D), Polyacrylamide Gel-Based DNA Microarray Method

  2013cites this paper
• Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors

  2012cites this paper
• La eficacia y toxicidad de la quimioterapia con gemcitabina y cisplatino en el carcinoma urotelial de vejiga avanzado/metastásico

  2012cites this paper
• A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer

  2012cites this paper
• Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.

  2012cites this paper
• Current chemotherapeutic strategies against bladder cancer

  2012cites this paper
• Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin

  2012cites this paper
• Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience.

  2012cites this paper
• [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].

  2012cites this paper
• 吉西他滨调整方案治疗晚期非小细胞肺癌的Ⅱ期临床试验

  2012cites this paper
• Elective bladder preservation with multimodality treatment for bladder cancer.

  2012cites this paper
• The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

  2012cites this paper
• Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients

  2012cites this paper
• Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

  2012cites this paper
• Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.

  2012cites this paper
• Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.

  2012cites this paper
• Chemotherapy for Metastatic Disease

  2012cites this paper
• A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.

  2011cites this paper
• Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer

  2011cites this paper
• Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

  2011cites this paper
• Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma

  2011cites this paper
• Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

  2011cites this paper
• Antitumor effects of combined carboplatin and gemcitabine in canine transitional cell carcinoma

  2011cites this paper
• New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer

  2011cites this paper
• Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.

  2011cites this paper
• Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

  2010cites this paper
• Clinical Cancer esearch cer Therapy : Clinical bition of Carboplatin-Induced DNA Interstrand Cross-link air by Gemcitabine in Patients Receiving these Drugs for R inum-Resistant Ovarian Cancer

  2010cites this paper
• Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.

  2010cites this paper
• Study of a Molecular Promoter for Enhancing Cisplatin Cancer Chemotherapy

  2010cites this paper
• Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer

  2010cites this paper
• Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells.

  2010cites this paper
• Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.

  2010cites this paper
• Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

  2010cites this paper
• Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

  2010cites this paper
• A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer.

  2010cites this paper
• Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes

  2010cites this paper
• Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma

  2009cites this paper
• Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non‐small‐cell lung cancer: Is thrombocytopenia predictable?

  2009cites this paper
• Cisplatin plus Gemcitabine Chemotherapy in Taxane/Anthracycline-Resistant Metastatic Breast Cancer

  2009cites this paper
• Combined gemcitabine and carboplatin therapy for carcinomas in dogs.

  2009cites this paper
• Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.

  2009cites this paper
• Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

  2009cites this paper
• Tolerability of Gemcitabine a nd Carboplatin Doublet T herapy in Cats with C arcinomas

  2009cites this paper
• The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.

  2009cites this paper
• Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study

  2009cites this paper
• Selective pulmonary artery perfusion for the treatment of primary lung cancer: Improved drug exposure of the lung.

  2009cites this paper
• Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.

  2009cites this paper
• Tolerability of gemcitabine and carboplatin doublet therapy in cats with carcinomas.

  2009cites this paper
• Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.

  2008cites this paper